Article

PanOptica licenses VEGF inhibitor

PanOptica Inc. has raised $30 million in financing, coinciding with the company?s successful licensing of exclusive worldwide ophthalmic rights to a selective inhibitor of vascular endothelial growth factor (PAN-90806, OSI Pharmaceuticals) in exchange for up-front cash, equity interest in PanOptica, and potential future milestones and royalties.

Mount Arlington, NJ-PanOptica Inc. has raised $30 million in financing, coinciding with the company’s successful licensing of exclusive worldwide ophthalmic rights to a selective inhibitor of vascular endothelial growth factor (VEGF) (PAN-90806, OSI Pharmaceuticals) in exchange for up-front cash, equity interest in PanOptica, and potential future milestones and royalties.

Specific financial terms of the agreement have not been disclosed.

The VEGF selective inhibitor involved in the transaction shows potential as a topical treatment for neovascular age-related macular degeneration (AMD).

“We’re thrilled to have completed our Series A financing, which enables us to advance [the VEGF selective inhibitor] through phase II clinical trials, complete a licensing deal for a second compound and develop it through phase II, and select a third asset, which we’re actively seeking,” said Paul Chaney, co-founder, president, and chief executive officer (CEO) of PanOptica.

PanOptica also has created a board of directors chaired by David Guyer, MD, founder and former CEO of Eyetech Pharmaceuticals and currently a partner of SV Life Sciences. Additional board members include Lutz Giebel, PhD, managing partner of SV Life Sciences; Kevin Starr, partner of Third Rock Ventures; and Chaney. Two independent board members will be appointed.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
© 2025 MJH Life Sciences

All rights reserved.